TELCON RF PHARMACEUTICAL Balance Sheet Health
Financial Health criteria checks 2/6
TELCON RF PHARMACEUTICAL has a total shareholder equity of ₩104.9B and total debt of ₩26.4B, which brings its debt-to-equity ratio to 25.2%. Its total assets and total liabilities are ₩140.4B and ₩35.5B respectively. TELCON RF PHARMACEUTICAL's EBIT is ₩965.3M making its interest coverage ratio 2.4. It has cash and short-term investments of ₩10.5B.
Key information
25.2%
Debt to equity ratio
₩26.44b
Debt
| Interest coverage ratio | 2.4x |
| Cash | ₩10.52b |
| Equity | ₩104.94b |
| Total liabilities | ₩35.47b |
| Total assets | ₩140.41b |
Recent financial health updates
Recent updates
Investors Shouldn't Be Too Comfortable With TELCON RF PHARMACEUTICAL's (KOSDAQ:200230) Earnings
Mar 26
TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:200230) Investors Are Less Pessimistic Than Expected
Mar 13Is TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Using Too Much Debt?
Apr 05Did Business Growth Power TELCON RF PHARMACEUTICAL's (KOSDAQ:200230) Share Price Gain of 218%?
Feb 03Financial Position Analysis
Short Term Liabilities: A200230's short term assets (₩33.0B) do not cover its short term liabilities (₩34.9B).
Long Term Liabilities: A200230's short term assets (₩33.0B) exceed its long term liabilities (₩546.4M).
Debt to Equity History and Analysis
Debt Level: A200230's net debt to equity ratio (15.2%) is considered satisfactory.
Reducing Debt: A200230's debt to equity ratio has increased from 12.3% to 25.2% over the past 5 years.
Debt Coverage: A200230's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: A200230's interest payments on its debt are not well covered by EBIT (2.4x coverage).